Skip to main content

Advertisement

Table 4 Bleeding control by treated site

From: Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy

Treated Site (N) Change in grade Baseline to End of RT n (%) Baseline to End of follow-up n (%) End of RT to End of follow-up n (%)
Uterovaginal (N=19) Worsened - 1 (5.3%) 2 (10.5%)
  No change 1 (5.3%) 1 (5.3%) 10 (52.6%)
  Improved 18 (94.7%) 15 (78.9%) 5 (26.3%)
  Missing - 2 (10.5%) 2 (10.5%)
Bladder (N=17) Worsened - 2 (11.8%) 5 (29.4%)
  No change 6 (35.3%) 4 (23.5%) 8 (47.1%)
  Improved 11 (64.7%) 10 (58.8%) 3 (17.6%)
  Missing - 1 (5.9%) 1 (5.9%)
Lung (N=10) Worsened - - -
  No change - - 6 (60.0%)
  Improved 10 (100.0%) 8 (80.0%) 2 (20.0%)
  Missing - 2 (20.0%) 2 (20.0%)
Upper GI (N=10) Worsened 1 (10.0%) 3 (30.0%) 2 (20.0%)
  No change - - 4 (40.0%)
  Improved 9 (90.0%) 6 (60.0%) 3 (30.0%)
  Missing - 1 (10.0%) 1 (10.0%)
Other (N=6)* Worsened - - -
  No change - - 5 (83.3%)
  Improved 6 (100.0%) 6 (100.0%) 1 (16.7%)
  1. Abbreviations: *including lower gastrointestinal (n=4), skin (n=1) and abdominal wall (n=1).